SYnAbs is awarded a major Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins
New primary monoclonal antibodies · 25. November 2022
Synabs announces a large Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins
Membrane Antibody Therapeutic Approach to Ion Channelopathies
SYnAbs' unique approach generating ultra-specific therapeutic monoclonals to ion channels and effectively treat channelopathies thanks to a unique antibody platform

SYnAbs launches unique anti-glucagon monoclonals
New primary monoclonal antibodies · 03. October 2022
SYnAbs monoclonals specific to glucagon without cross-reaction to GLP-1, Glicentin, Oxyntomodulin and Proglucagon, to diagnose diabetes and glucagonomas diseases
SYnAbs signs a research agreement with Domain Therapeutics to discover therapeutic antibodies on GPCRs
SYnAbs and Domain Therapeutics enter into a strategic partnership for the discovery and development of therapeutic antibodies targeting complex G Protein Coupled Receptor targets for immuno-oncology indications

G protein-coupled endothelin receptors and their natural and therapeutic ligands
From the discovery of an unique peptide ligand to the clinical relevance of ETA and ETB receptors and the current therapeutic pipeline of small molecules and monoclonal antibodies targeting these GPCR transmembrane proteins
Glutamate transporter : a brief history of excitatory amino acid transmembrane proteins
SYnAbs has developed R&D and therapeutic monoclonal antibodies against transporters and ion channel such as glutamate EAAT transmembrane targets thanks to peptide and syngeneic cell immunization strategies

TACA, promising oncology targets?
SYnAbs develops therapeutic IgG antibodies highly specific to carbohydrates by combining unique technologies and expertise to break immune tolerance in rat-LOU and transgenic animal species
Therapeutic trends of G protein-coupled receptor drugs as Antibody Drug Conjugates candidates
SYnAbs can help you develop therapeutic antibody-drug conjugates by specifically targeting transmembrane proteins using innovative proprietary technologies.

CX3CR1, GPCR CX3C chemokine receptor 1 (CX3CR1): transmembrane receptor of therapeutic interest?
SYnAbs discovers antibodies to transmembrane proteins including GPCR chemokine receptors thanks to unique cell immunization technology and expertise
Immuno-Oncology Therapeutic Potential of Adenosine Receptors: Targeting the Purinergic Pathway
SYnAbs develops therapeutic monoclonal antibodies with agonistic or antagonistic effects to highly homologous G Protein-Coupled Receptors transmembrane proteins

Show more